Genetic abnormalities and pathophysiology of MDS

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) are clonal myeloid malignancies.
• Characterized by peripheral blood cytopenia and ineffective hematopoiesis.
• MDS frequently progresses to acute myeloid leukemia.

Purpose of the Study:

• To review recent advancements in understanding the molecular pathogenesis of MDS.
• To highlight the role of genetic defects in MDS development.
• To inform the development of targeted therapies for MDS.

Main Methods:

• Analysis of cytogenetic abnormalities in MDS patients.
• Application of advanced genomic technologies like SNP arrays and next-generation sequencing.
• Identification and characterization of recurrent somatic gene mutations.

Main Results:

• Chromosomal abnormalities (e.g., 5q, 7q deletions, trisomy 8) found in 50-60% of MDS.
• Haploinsufficient gene deletions identified via newer genomic technologies.
• Recurrent mutations in >50 genes (RNA splicing, epigenetic modifiers) found in 80-90% of MDS.
• TP53 mutations linked to aggressive disease and 5q deletion.

Conclusions:

• Genetic defects, including chromosomal abnormalities and gene mutations, are central to MDS pathogenesis.
• Advances in molecular profiling reveal specific genetic alterations driving MDS.
• A deeper understanding of MDS molecular subgroups will facilitate novel therapeutic strategies.